Clinical Inertia In The Individualisation Of Care For Patients With Diabetes - 12 Nov

Presented by Dr Paivi Maria Paldanius

Thursday 12 November, 8 - 9am
Lecture Theatre 2, Monash Medical Centre

Dr. Päivi Maria Paldánius is Director, Global Medical Affairs Diabetes and Metabolism at Novartis Pharma AG, Switzerland. She graduated from a unique research-oriented medicine programme (MMS) piloted at Karolinska Institute, Stockholm, Sweden, and has also completed Nordplus scholar studies in neuropharmacology at the Helsinki University and more recently, clinical paediatric graduate school studies as a part of her PhD studies at the Children’s Hospital, Helsinki University Central Hospital. She joined Novartis in 2006 and has been contributing to the clinical programmes within diabetes and metabolism as Regional European Medical Adviser, later as Global Principle Medical Scientific Expert and after year 2013 as Director, Global Medical Affairs Diabetes and Metabolism. Today she is the medical lead of the VERIFY study and has designed, implemented and published unique clinical studies and clinical programmes such as the INTERVAL study addressing the individualised targets in elderly persons with T2DM or the Time2DoMore programme addressing the barriers to optimised diabetes care and perceptions and reasons behind clinical inertia.

In parallel with her pharmaceutical career Päivi Paldánius is also a member of an academic research group at Children’s Hospital, Helsinki University Central Hospital. Her academic research interests have always focused on endocrinology, especially targeting mechanisms behind imbalances in bone metabolism and glucose tolerance in a cohort of young adults born prematurely with very low birth weight.